<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829604</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-Breast-03</org_study_id>
    <nct_id>NCT04829604</nct_id>
  </id_info>
  <brief_title>ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)</brief_title>
  <acronym>ACE-Breast03</acronym>
  <official_title>A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM-1 or T-DXd, and/or Tucatinib-containing Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ambrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ambrx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose&#xD;
      Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing&#xD;
      Regimens&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer&#xD;
      Patients whose disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or&#xD;
      Tucatinib-containing Regimens. The ARX788 will be administered every 4 weeks (Q4W)&#xD;
      intravenous (IV) infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One single arm, open label with intravenous infusion of ARX788</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 Years</time_frame>
    <description>The confirmed objective response rate (ORR) of ARX788 based on RECIST 1.1 in HER2-positive breast cancer subjects whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.&#xD;
The ORR is defined as the number of subjects with a BOR of CR or PR divided by the number of response evaluable subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>DOR is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first, will be computed for subjects with a BOR of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best percent change in the sum of the longest diameters of measurable tumors</measure>
    <time_frame>2 years</time_frame>
    <description>The percent change at the best response data point compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>2 year</time_frame>
    <description>BOR is defined as the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>DCR is defined as the proportion of complete response (CR), partial response (PR), and stable disease (SD) rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>PFS is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable subjects. Subjects will be censored at time of subsequent therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 year</time_frame>
    <description>Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause). Subjects who are alive will be censored at the last known time that the subject was alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects experiencing adverse event TEAEs</measure>
    <time_frame>2 years</time_frame>
    <description>Patient safety and adverse events (AEs) will be evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. All AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) for ARX788, total antibody, and pAF-AS269</measure>
    <time_frame>Cycle 1 and cycle 3</time_frame>
    <description>Pharmacokinetic parameter maximum serum concentration (Cmax) for ARX788, total antibody, and pAF-AS269</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough) for ARX788, total antibody, and pAF-AS269</measure>
    <time_frame>Cycle 1 and cycle 3</time_frame>
    <description>Pharmacokinetic parameter trough concentration (Ctrough) for ARX788, total antibody, and pAF-AS269</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) for ARX788, total antibody, and pAF-AS269</measure>
    <time_frame>Cycle 1 and cycle 3</time_frame>
    <description>Pharmacokinetic parameter area under the serum concentration-time curve (AUC) for ARX788, total antibody, and pAF-AS269</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs)</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of anti-drug antibodies (ADAs) following intravenous administration of ARX788 in participants with HER2-positive metastatic breast cancer</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HER2 Positive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This global Phase 2 study is designed to assess anticancer activity and safety of ARX788 in HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.&#xD;
The investigational medicinal product (IMP), ARX788, will be administered every 4 weeks (Q4W) by intravenous (IV) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARX788</intervention_name>
    <description>The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269</description>
    <arm_group_label>HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory</arm_group_label>
    <other_name>antibody drug conjugate (ADC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and older&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status ≤ 1&#xD;
&#xD;
          -  Metastatic breast cancer subjects previously treated with T DM1, and/or T-DXd, and/or&#xD;
             tucatinib-containing regimens.&#xD;
&#xD;
          -  Presence of at least one measurable lesion per RECIST v 1.1&#xD;
&#xD;
          -  Subjects must have an adequate tumor sample available for confirmation of HER2 status&#xD;
&#xD;
          -  Subjects with stable brain metastases&#xD;
&#xD;
          -  Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved&#xD;
             to Grade ≤1 as per the NCI-CTCAE v 5.0, except alopecia.&#xD;
&#xD;
          -  Adequate organ functions&#xD;
&#xD;
          -  Willing and able to understand and sign an informed consent inform and to comply with&#xD;
             all aspects of the protocol.&#xD;
&#xD;
          -  Female subjects must be surgically sterile, or have a monogamous partner who is&#xD;
             surgically sterile, or at postmenopausal, or who commits to use an acceptable form of&#xD;
             birth control; male subjects must be sterile (biologically or surgically) or commit to&#xD;
             the use of a reliable method of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any subject who meets any of the following criteria is excluded from the study:&#xD;
&#xD;
          -  History of allergic reactions to any component of ARX788.&#xD;
&#xD;
          -  Prior history of interstitial lung disease, pneumonitis, or other clinically&#xD;
             significant lung disease within 12 months&#xD;
&#xD;
          -  History of ocular events, or any current ongoing active ocular infections.&#xD;
&#xD;
          -  History of congestive heart failure, unstable angina pectoris, unstable atrial&#xD;
             fibrillation, or cardiac arrhythmia within 12 months prior to enrollment&#xD;
&#xD;
          -  Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0)&#xD;
&#xD;
          -  History of unstable central nervous system (CNS) metastases&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease (eg, clinically significant&#xD;
             cardiovascular, pulmonary, or metabolic diseases)&#xD;
&#xD;
          -  Any uncontrollable intercurrent illness, infection (including subjects with active,&#xD;
             symptomatic Covid-19 infections), or other conditions that could limit study&#xD;
             compliance or interfere with assessments.&#xD;
&#xD;
          -  Exposure to any other investigational or commercial anticancer agents or therapies&#xD;
             administered with the intention to treat malignancy within 14 days before the first&#xD;
             dose of ARX788.&#xD;
&#xD;
          -  Clinically significant surgical intervention (excluding diagnostic biopsy) within 21&#xD;
             days of the first dose of ARX788&#xD;
&#xD;
          -  Radiotherapy administered less than 21 days prior to the first dose of ARX788, or&#xD;
             localized palliative radiotherapy administered less than 7 days prior to the first&#xD;
             dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on&#xD;
             NCI-CTCAE v 5.0.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Known active HCV, HBV, and/or HIV infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ambrx</last_name>
    <role>Study Director</role>
    <affiliation>Ambrx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Inquiry</last_name>
    <phone>(858) 875-2400</phone>
    <email>breast03trialinquiry@ambrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92882</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Ali, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Sami Ali, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Lu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Janice Lu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Hurvitz, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Sara Hurvitz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsun Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mukul Gupta, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Mukul Gupta, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chan, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>David Chan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>West Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vi K Chiu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Vi K Chiu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hematology Consultants, PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamal G Misleh, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jamal G Misleh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petros Nikolinakos, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Personal Physicians</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Riseberg, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>David Riseberg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kashif Ali, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Kashif Ali, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XCancer/Central Care Cancer Center</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonid Shunyakov, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Leonid Shunyakov, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nusayba Bagegni, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Nusayba Bagegni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Block, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Margaret Block, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anu Thummala, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Anu Thummala, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology Hematology Consultants</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Fontaine, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Annette Fontaine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Novik, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yelena Novik, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Oncology</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Andersen, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jay Andersen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Surgical Specialists</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Patt, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Debra Patt, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce O'Shaughnessy, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Joyce O'Shaughnessy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Stokoe, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Christopher Stokoe, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Richards, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Donald Richards, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Danso, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Danso, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sibel Blau, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Sibel Blau, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandria Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Cuff, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Katherine Cuff, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia McCartney, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Amelia McCartney, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Breast Cancer Research Centre - WA</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlene Chan, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Arlene Chan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-postive</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Antibody drug</keyword>
  <keyword>Metastatic</keyword>
  <keyword>ARX788</keyword>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

